Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugatesBen‐Quan Shen, Jagath R. Junutula, Keyang Xu et al.|Nature Biotechnology|2012Cited by 997
Antibody-Drug Conjugates for the Treatment of Non–Hodgkin's Lymphoma: Target and Linker-Drug SelectionAndrew G. Polson, Allen Ebens, Jill Calemine-Fenaux et al.|Cancer Research|2009Cited by 248
Antibody Conjugation of a Chimeric BET Degrader Enables <i>in vivo</i> ActivityThomas H. Pillow, Peter S. Dragovich, Brandon Latifi et al.|ChemMedChem|2019Cited by 193
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphomaAndrew G. Polson, Allen Ebens, Shang‐Fan Yu et al.|Blood|2007Cited by 172
Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor EfficacyPeter S. Dragovich, Xiaoyu Zhu, Thomas H. Pillow et al.|Journal of Medicinal Chemistry|2021Cited by 168